Compare AstraZeneca plc (AZN) vs Walt Disney Co (DIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Walt Disney Co — how do they compare? AstraZeneca plc trades at $166.7 (market cap $253.13B), while Walt Disney Co trades at $95.8 (market cap $166.48B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | DIS | |
|---|---|---|
Market Cap | $253.13B | $166.48B |
Sector | Health | Media |
52-Week High | $209.48 | $122.94 |
52-Week Low | $137.44 | $92.40 |
Enterprise Value | $279.37B | $208.16B |
Dividend Yield | 1.92% | 1.56% |
Volume | — | 7,546,013 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Disney (DIS) trades at $95.87, up 0.25% with a P/E of 15.36 and strong earnings beats in recent quarters. The company shows robust fundamentals with $94.43B revenue and $12.40B net income in 2025, though technical indicators signal bearish momentum. Recent news highlights advertising opportunities with major events and regulatory challenges with the FCC.
Outlook remains positive with analyst consensus at $125.60 target, representing 31% upside. Key opportunities include sports broadcasting rights and theme park recovery, while risks involve box office performance and regulatory pressures. The stock offers value with improving profitability and strong cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →
